First Independent Booth Draws Over 1,000 Visitors
Active Partnership Meetings with Global Top 40 Clients
Samsung Biologics announced on October 10 that it had successfully concluded its participation in "Bio Japan 2025," Asia's largest pharmaceutical and bio exhibition, held in Yokohama, Japan, from October 8 to 10.
Participating for the third consecutive year since 2023, Samsung Biologics set up its own independent booth for the first time this year, actively engaging in order acquisition activities. The company also unveiled a new brand and hosted presentation sessions to showcase its competitiveness, further solidifying its position as a leading global contract development and manufacturing organization (CDMO).
Samsung Biologics booth at Bio Japan 2025, Asia's largest pharmaceutical and bio exhibition held on the 8th. Samsung Biologics
During the event, the Samsung Biologics booth attracted approximately 1,000 visitors, drawing significant attention. The company highlighted its differentiated strengths to booth visitors, including its world-leading production capacity of 784,000 liters and next-generation modality service capabilities. Samsung Biologics also held numerous partnership meetings with Japanese pharmaceutical companies, as well as with global top 40 clients and potential customers.
Additionally, Samsung Biologics introduced its new contract manufacturing (CMO) brand, "ExellenS™," for the first time at this event. ExellenS is a manufacturing framework built on the core values of Equivalency and Speed, reflecting the company's commitment to delivering pharmaceuticals of consistent quality to customers swiftly.
Equivalency refers to establishing optimized production designs based on accumulated expertise and applying them to future manufacturing facilities, thereby ensuring consistency in quality and production systems across all plants. Speed signifies building an agile production system that can rapidly supply pharmaceuticals at the timing required by global clients, based on optimized production designs and operational processes.
Samsung Biologics plans to maintain its manufacturing competitiveness as a global top-tier CDMO by integrating not only its four core values-Customer Excellence, Operational Excellence, Quality Excellence, and People Excellence (the "4E")-but also the "3S" principles of Simplification, Standardization, and Scalability.
On the first day of the event, James Choi, Executive Vice President of Business Support, and Kevin Sharp, Executive Vice President of Sales & Operations, gave presentations explaining the advantages of CDMO outsourcing and the growth potential of next-generation modalities. Global industry professionals in attendance showed great interest in Samsung Biologics' wide-ranging service capabilities and proven manufacturing expertise, engaging in active Q&A sessions.
John Rim, CEO of Samsung Biologics, stated, "Bio Japan 2025 was an opportunity to once again demonstrate our advanced technological capabilities and reliability onsite," adding, "We will continue to expand partnerships with global clients and seek various collaboration opportunities to deliver high-quality biopharmaceuticals quickly."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
